Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Hackensack Meridian Health
Baylor College of Medicine
Hutchmed
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Werewolf Therapeutics, Inc.
Eli Lilly and Company
University of California, San Diego
City of Hope Medical Center
Merck Sharp & Dohme LLC
Therapeutic Advances in Childhood Leukemia Consortium
University of California, San Diego
M.D. Anderson Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Trishula Therapeutics, Inc.
Hutchmed
Ipsen
Northwestern University
Gilead Sciences
American Regent, Inc.
Ohio State University Comprehensive Cancer Center
Amgen
National Institutes of Health Clinical Center (CC)
BeiGene
Novartis
UNC Lineberger Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
Celgene
Pacylex Pharmaceuticals
Washington University School of Medicine
Merck Sharp & Dohme LLC
Shattuck Labs, Inc.
Daiichi Sankyo
Children's Oncology Group
GlaxoSmithKline
Ipsen
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Therapeutic Advances in Childhood Leukemia Consortium
Pfizer
Children's Oncology Group
AstraZeneca
BeiGene
Acerta Pharma BV
National Institutes of Health Clinical Center (CC)